TY - JOUR
T1 - Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors
AU - Kober, Kord M.
AU - Mazor, Melissa
AU - Abrams, Gary
AU - Olshen, Adam
AU - Conley, Yvette P.
AU - Hammer, Marilyn
AU - Schumacher, Mark
AU - Chesney, Margaret
AU - Smoot, Betty
AU - Mastick, Judy
AU - Paul, Steven M.
AU - Levine, Jon D.
AU - Miaskowski, Christine
N1 - Funding Information:
This study was funded by the NCI (CA151692) and the American Cancer Society (IRG-97-150-13). Dr. Miaskowski is supported by a grant from the American Cancer Society and NCI (CA168960). This project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through University of California San Francisco-Clinical and Translational Science Institute grant number UL1 TR000004. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Recruitment was facilitated by Dr. Susan Love Research Foundation's Army of Women® Program. The authors declare no conflicts of interests.
Funding Information:
This study was funded by the NCI ( CA151692 ) and the American Cancer Society ( IRG-97-150-13 ). Dr. Miaskowski is supported by a grant from the American Cancer Society and NCI ( CA168960 ). This project was supported by the National Center for Advancing Translational Sciences , National Institutes of Health , through University of California San Francisco-Clinical and Translational Science Institute grant number UL1 TR000004 . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Recruitment was facilitated by Dr. Susan Love Research Foundation's Army of Women ® Program. The authors declare no conflicts of interests.
Publisher Copyright:
© 2018 American Academy of Hospice and Palliative Medicine
PY - 2018/12
Y1 - 2018/12
N2 - Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors’ symptom burden, functional status, and QOL.
AB - Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors’ symptom burden, functional status, and QOL.
KW - Paclitaxel
KW - balance
KW - cancer
KW - chemotherapy
KW - pain
KW - peripheral neuropathy
KW - quality of life
KW - stress
KW - survivor
UR - http://www.scopus.com/inward/record.url?scp=85054165306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054165306&partnerID=8YFLogxK
U2 - 10.1016/j.jpainsymman.2018.08.017
DO - 10.1016/j.jpainsymman.2018.08.017
M3 - Article
C2 - 30172061
AN - SCOPUS:85054165306
VL - 56
SP - 908-919.e3
JO - Journal of Pain and Symptom Management
JF - Journal of Pain and Symptom Management
SN - 0885-3924
IS - 6
ER -